GW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

May 09, 2017

- Epidiolex® NDA submission expected mid-year–

- New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -

-Conference call today at 4:30 p.m. EST-

London, UK, 9 May 2017: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter ended 31 March 2017.                              

“Our primary focus is on the submission of the Epidiolex NDA, which is expected in the middle of this year. Based on the efficacy and safety profile, we are confident in the prospects for an Epidiolex approval and continue to expand the commercial organization in preparation for a highly successful launch,” stated Justin Gover, GW’s Chief Executive Officer. “Beyond Epidiolex, we continue to advance a number of additional exciting clinical programs.”


  • Epidiolex (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS)

    • Regulatory:

      • NDA submission for both Dravet and LGS indications expected mid-2017
      • Expected EU regulatory submission in H2 2017
      • Rare pediatric disease designation conditionally granted by FDA – pre-cursor to priority review voucher
      • Orphan Designation granted by European Medicines Agency (EMA) in the treatment of LGS
    • Clinical:
      • New Phase 3 LGS data presented at the American Academy of Neurology (AAN) Annual Meeting in April 2017
      • 3 podium presentations at AAN
      • Phase 3 Dravet syndrome trial accepted for publication in high status journal with publication expected in Q2
      • Phase 3 trial in Tuberous Sclerosis Complex ongoing
      • Part A of two-part Phase 3 trial in Infantile Spasms underway
    • Management Update:
      • Scott Giacobello appointed as Chief Financial Officer
      • Adam George appointed as Managing Director – UK
    • Manufacturing scale-up on track to deliver significant commercial launch inventory:
      • Pre-NDA CMC meeting held with FDA in November 2016
      • Successful UK regulatory Good Manufacturing Practice (GMP) inspection of GW manufacturing facility in December 2016. On track for FDA GMP inspection anticipated in H2 2017
    • Expanded access program and open label extension:
      • Over 1,500 patients now exposed to Epidiolex treatment
      • 97 percent of patients who complete Phase 3 trials have entered long term extension
    • Commercial:
      • U.S. commercial team build well underway and pre-launch preparations advancing well
      • EU commercial team now being established
    • Intellectual Property
      • 13 distinct patent families in prosecution relating to the use of CBD in the treatment of epilepsy; decisions expected for several patents towards end 2017 and H1 2018
  • Other cannabinoid pipeline product candidates:
    • CBDV Phase 2 partial-onset epilepsy study in adults fully enrolled. Data expected Q4 2017
    • CBDV in field of autism spectrum disorders
      • Expanded access IND granted by FDA for 10 patients with autism
      • Open label study in Rett syndrome to commence Q4 2017 and Phase 2 placebo-controlled trial in planning for Q1 2018.  
      • Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
      • Phase 1 trial complete. Phase 2 protocol discussions with FDA in H2 2017
      • Orphan Drug and Fast Track Designations granted from FDA and EMA
    • THC:CBD for Glioma
      • Positive Phase 2 placebo-controlled data in Recurrent Glioblastoma Multiforme (GBM)
      • Abstract accepted at ASCO
      • Orphan Drug Designation from FDA and EMA


  • Cash and cash equivalents at 31 March 2017 of £306.3 million ($383.9 million) compared to £374.4 million as at 30 September 2016
  • Revenue for the six months ended 31 March 2017 of £3.7 million ($4.6 million) compared to £6.3 million for the six months ended 31 March 2016
  • Loss for the six months ended 31 March 2017 of £50.0 million ($62.6 million) compared to £34.5 million for the six months ended 31 March 2016

    Solely for the convenience of the reader, the above balances have been translated into U.S. dollars at the rate on 31 March 2017 of $1.25331 to £1. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date.

    Conference Call and Webcast Information

    GW Pharmaceuticals will host a conference call and webcast to discuss the second quarter 2017 financial results today at 4:30 pm EST. To participate in the conference call, please dial 800-860-2442 (toll free from the U.S. and Canada) or 412-858-4600 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010, (international):1-919-882-2331. For both dial-in numbers please use conference ID # 13661781.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit

Forward-looking statements

This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex and Epidiolex and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


GW Pharmaceuticals plc


Stephen Schultz, VP Investor Relations

401 500 6570

Sam Brown (U.S. Media Enquiries)


Mike Beyer

312 961 2502




Recent News